Suppr超能文献

红光响应的 Ru 配合物光动力治疗剂用于溶酶体定位。

Red-Light-Responsive Ru Complex Photosensitizer for Lysosome Localization Photodynamic Therapy.

机构信息

State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.

Ningbo Institute of Dalian University of Technology, 26 Yucai Road, Jiangbei District, Ningbo 315016, China.

出版信息

ACS Appl Mater Interfaces. 2021 May 5;13(17):19572-19580. doi: 10.1021/acsami.0c22551. Epub 2021 Apr 26.

Abstract

Photoresponsive ruthenium (Ru) complexes have been extensively studied in the photodynamic therapy (PDT) of cancer. The metal-to-ligand charge transfer (MLCT) absorption maximum of most Ru complexes is located in the short-wavelength visible region, which is well suited for superficial tumors but shows inefficient therapeutic effects for more deep-seated ones. Moreover, Ru complexes are primarily located in the mitochondria or nucleus, always resulting in high levels of dark toxicity and DNA mutation. Herein, we reported a new ruthenium complex (Ru-I) for red-light-triggered PDT. The activation wavelength of Ru-I is successfully extended to 660 nm. Importantly, the complex photosensitizer can be quickly taken up by cancer cells and selectively accumulated in the lysosome, an ideal localization for PDT purposes. Intratumoral injection of Ru-I into tumor-bearing mice achieved excellent therapeutic effects and thus holds great promise for applications in lysosome localization photodynamic therapy.

摘要

光响应钌(Ru)配合物在癌症的光动力疗法(PDT)中得到了广泛研究。大多数 Ru 配合物的金属-配体电荷转移(MLCT)吸收最大值位于短波长可见光区域,这非常适合治疗表浅肿瘤,但对于较深层次的肿瘤治疗效果不佳。此外,Ru 配合物主要位于线粒体或细胞核中,总是导致高暗毒性和 DNA 突变。在此,我们报道了一种用于红光触发 PDT 的新型钌配合物(Ru-I)。Ru-I 的激活波长成功扩展到 660nm。重要的是,该配合物光敏剂可以被癌细胞快速摄取,并选择性地积累在溶酶体中,这是 PDT 的理想定位。将 Ru-I 瘤内注射到荷瘤小鼠中实现了优异的治疗效果,因此在溶酶体定位光动力疗法中有很大的应用前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验